EVOLUTION OF BIOLOGICAL PARAMETERS IN THE METABOLIC SYNDROME

Authors

  • Roxana GANCEANU-RUSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Liliana MITITELU-TARTAU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. STATESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Mihaela BOANCA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R.V. LUPUSORU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Nicoleta DIMA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Elena REZUS “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. REZUS “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Catalina-Elena LUPUSORU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Keywords:

METABOLIC SYNDROME, CARDIOVASCULAR DISEASES, BIOLOGICAL PARAMETERS, PHARMACOLOGICAL THERAPY

Abstract

The metabolic syndrome is responsible for the threefold increase of the atherosclerotic cardiovascular diseases and for the increase of the mortality due to these disorders compared to the general population. Aim: To evaluate the biochemistry dynamics and the specific medication in patients diagnosed with metabolic syndrome. Materials and methods: The study was carried out in the 3rd Medical Clinic of the “Sf. Spiridon” County Clinical Emergency Hospital of Iasi, being a retrospective study and including 250 patients which fulfilled at least three of the five defining criteria of the metabolic syndrome. Results: It was obtained the improvement of the inflammatory metabolic syndrome through the decrease of the fibrinogen and of the C-reactive protein (p=0.001). It was observed the fact that, both in men as well as in women, serum value of the uric acid proved to be significant in hypertensive subjects, a statistically significant decrease being observed in the patients treated with Candesartan. Conclusions: Obesity and especially the central adiposity is the dominant risk factor for the development of the type 2 diabetes mellitus, which usually is accompanied by the arterial hypertension due to a common physiopathology. Although the pharmacologic therapy is often necessary, a very important element remains the lifestyle change which represents the only full therapeutic approach which can reduce the resistance to insulin and visceral obesity.

Author Biographies

  • Roxana GANCEANU-RUSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    “Grigore T. Popa” University of Medicine and Pharmacy Iasi
    Faculty of Medicine
    Department of Morpho-Functional Sciences (II)

  • Liliana MITITELU-TARTAU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (II)

  • C. STATESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (I)
    “Prof. Dr. George I. M. Georgescu” Institute of Cardiovascular Diseases Iasi

  • Mihaela BOANCA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (II)

  • R.V. LUPUSORU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (II)

  • Nicoleta DIMA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (I)
    “Sf. Spiridon” County Clinical Emergency Hospital, 3rd Medical Clinic

  • Elena REZUS, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)
    Recovery Clinical Hospital, 1st Rheumatology Clinic

  • C. REZUS, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (I)
    “Sf. Spiridon” County Clinical Emergency Hospital, 3rd Medical Clinic

  • Catalina-Elena LUPUSORU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (II)

References

1. Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi-Hashiani A et al. Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PLoS One 2017; 12(3): e0170361.
2. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015; 313(19): 1973-1974.
3. de Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of metabolic syndrome in Brazilian adults: a systematic review. BMCPublic Health 2013; 13: 1198-1204.
4. Lao XQ, Zhang YH, Wong MC, Xu YJ, Xu HF, Nie SP et al. The prevalence of metabolic syndrome and cardiovascular risk factors in adults in southern China. BMC Public Health 2012; 12: 64-68.
5. DeBoer MD, Gurka MJ. Clinical utility of metabolic syndrome severity scores: considerations for practitioners. Diabetes Metab Syndr Obes 2017; 10: 65-72.
6. Mulè G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol 2014; 6(9): 890-907.
7. Mitu F, Cobzaru R, Leon MM. Influence of metabolic syndrome profile on cardiovascular risk. Rev Med Chir Soc Med 2013; 117(2): 308-314.
8. Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H et al. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci. Rep 2015; 5: 13058-13064.
9. Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int. J. Mol. Sci 2016; 17(3): 367-372.
10. Music M, Dervisevic A, Pepic E, Lepara O, Fajkic A, Ascic-Buturovic B et al. Metabolic Syndrome and Serum Liver Enzymes Level at Patients with Type 2 Diabetes Mellitus. Med. Arch 2015; 69(4): 251-255.
11. Rezuş E, Leon Constantin MM, Rezuş C. Correlation Between the Hyperuricemia and Metabolic Syndrome. Rev. Chim 2015; 66(7): 1015-1018.
12. Jayashankar CA, Andrews HP, Vijayasarathi, Pinnelli VB, Shashidharan B, Nithin Kumar HN et al. Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus. J. Nat. Sci. Biol. Med 2016; 7(2): 161-165.
13. Mazza A, Lenti S, Schiavon L, Del Monte A, Townsend DM, Ramazzina E et al. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. Biomed Pharmacother 2017; 86: 590-594.
14. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relation-ship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53(4): 316-322.
15. Mitu F, Rezus E, Banu C, Jufa C, Mitu O, Dima-Cozma C. Inflammatory markers in hypertensive patients and influence of some associated metabolic risk factor. Rev Med Chir Soc Med 2014; 118(3): 631-636.
16. Kovacs T, Vas T, Kovesdy CP, Kesõi I, Sagi B, Wittmann I et al. Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. Clin Kidney J 2013; 6(4): 395-401.
17. Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo G et al. Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS One 2017; 12(4): e0176058.
18. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED et al. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol 2013; 8(6): 945-952.

Additional Files

Published

2017-09-30